See patients who may be appropriate for Corlanor®

Click on a patient type below:
MAX DOSE BETA-BLOCKER
RECENTLY HOSPITALIZED
WORSENING SYMPTOMS OF HF

For patients with stable, symptomatic chronic HF with LVEF 35% and in sinus rhythm with resting heart rate 70 bpm:

Add Corlanor® for patients unable to tolerate max dose of beta-blocker1
GEORGE

Unable to tolerate max dose beta-blocker

Due to symptomatic hypotension and erectile dysfunction

WORSENING SYMPTOMS OF HF

  • Shortness of breath
  • Increased fatigue

ELEVATED RESTING HR

78 bpm sinus rhythm

MAX-TOLERATED BETA-BLOCKER DOSE

Metoprolol succinate 25 mg once daily [recently reduced to lower dose]
Corlanor patient

LVEF

BP (mm/Hg)

NYHA CLASSIFICATION

34%

94/65

Class II

ADDITIONAL MEDICATIONS

  • Enalapril 10 mg 2x/day
  • Furosemide 80 mg/day
This is a hypothetical patient.

For patients with stable, symptomatic chronic HF with LVEF 35% and in sinus rhythm with resting heart rate 70 bpm:

Add Corlanor® for stabilized patients after recent hospitalization1
LINDA

Recently hospitalized for worsening HF

Hemodynamically stable after discharge 7 days ago

WORSENING SYMPTOM OF HF

Continued shortness of breath

ELEVATED RESTING HR

84 bpm sinus rhythm

MAX-TOLERATED BETA-BLOCKER DOSE

Carvedilol 12.5 mg 2x/day
Corlanor patient

LVEF

BP (mm/Hg)

NYHA CLASSIFICATION

32%

100/60

Class III

ADDITIONAL MEDICATIONS

  • Enalapril 10 mg 2x/day
  • Spironolactone 25 mg once daily
  • Furosemide 40 mg 2x/day
This is a hypothetical patient.

For patients with stable, symptomatic chronic HF with LVEF 35% and in sinus rhythm with resting heart rate 70 bpm:

Add Corlanor® for symptomatic patients1
JAMES

Worsening symptoms of HF

Patient is also renally impaired and has an ICD implant

Worsening symptoms of HF

  • Persistent dyspnea and two-pillow orthopnea
  • Experiencing increased fatigue
  • Diminishing exercise capacity

ELEVATED RESTING HR

88 bpm sinus rhythm

MAX-TOLERATED BETA-BLOCKER DOSE

Carvedilol 6.25 mg 2x/day
Corlanor patient

LVEF

BP (mm/Hg)

NYHA CLASSIFICATION

30%

95/60

Class III

ADDITIONAL MEDICATIONS

  • Furosemide 80 mg once daily
  • Hydralazine 75 mg 3x/day
  • Isosorbide dinitrate 40 mg 3x/day
This is a hypothetical patient.

BP = blood pressure; BPM = beats per minute; HF = heart failure; HR = heart rate; ICD = implantable cardioverter defibrillator; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.

Reference
  1. Corlanor® (ivabradine) Prescribing Information, Amgen.
IMPORTANT SAFETY INFORMATION
SEE MORELESS

IMPORTANT SAFETY INFORMATION Contraindications: Corlanor® is contraindicated in patients with acute decompensated heart failure, blood pressure < 90/50 mmHg, sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular block (unless a functioning demand pacemaker is present), a resting heart rate < 60 bpm prior to treatment, severe hepatic impairment, pacemaker dependence (heart rate maintained exclusively by the pacemaker), and concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors.

Fetal Toxicity: Corlanor® may cause fetal toxicity when administered to a pregnant woman based on embryo-fetal toxicity and cardiac teratogenic effects observed in animal studies. Advise females to use effective contraception when taking Corlanor®.

Atrial Fibrillation: Corlanor® increases the risk of atrial fibrillation. The rate of atrial fibrillation in patients treated with Corlanor® compared to placebo was 5% vs. 3.9% per patient-year, respectively. Regularly monitor cardiac rhythm. Discontinue Corlanor® if atrial fibrillation develops.

Bradycardia and Conduction Disturbances: Bradycardia, sinus arrest and heart block have occurred with Corlanor®. The rate of bradycardia in patients treated with Corlanor® compared to placebo was 6% (2.7% symptomatic; 3.4% asymptomatic) vs. 1.3% per patientā€year, respectively. Risk factors for bradycardia include sinus node dysfunction, conduction defects, ventricular dyssynchrony, and use of other negative chronotropes. Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsades de pointes, especially in patients with risk factors such as use of QTc prolonging drugs.

Concurrent use of verapamil or diltiazem also increases Corlanor® exposure, contributes to heart rate lowering, and should be avoided. Avoid use of Corlanor® in patients with 2nd degree atrioventricular block unless a functioning demand pacemaker is present

Adverse Reactions: The most common adverse drug reactions reported at least 1% more frequently with Corlanor® than placebo and that occurred in more than 1% of patients treated with Corlanor® were bradycardia (10% vs. 2.2%), hypertension or increased blood pressure (8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%).

In postmarketing experience, torsades de pointes has been observed.


INDICATION

Corlanor® (ivabradine) is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction 35%, who are in sinus rhythm with resting heart rate 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

back to top